Hey Snackers,
Some buy a sports car or a house in Boca when they retire. Jeff Bezos is going to space.
While Bezos and his brother packed to board a Blue Origin rocket (Hawaiian shirt optional), stocks barely budged yesterday.
Fly like a G7... and drop bad news on Big Tech. The Group of Seven = the US, UK, Canada, France, Germany, Italy, and Japan. The G7 met in London over the weekend — and left with some tea to spill: the countries agreed that multinational companies should pay a minimum tax rate of at least 15% in each country in which they operate.
The luck of the Irish... may end. The deal marks a big step toward potentially adopting a 15% global minimum corporate-tax rate. That Dublin office = not so clutch anymore. Companies would have to pay the minimum rate regardless of where they're based. The agreement aims to stop large multinationals from seeking out tax havens — and force them to pay more of their income to governments. But it still has to go through the G20, which includes China, India, and other developing economies.
This could level the playing field... and end the "race to the bottom." For decades, countries have been competing with each other to attract corporate investment for economic growth. The main way to do that: lower companies' taxes. In 2000, more than 55 countries had corporate tax rates above 30% — now, fewer than 20 do. President Biden wants to raise corporate taxes in the US to fund government programs. The admin is backing a 15% global minimum to help keep the US competitive.
Not vax-related... for once. The Food and Drug Administration has made headlines for another reason. Yesterday, the FDA approved Biogen's Alzheimer’s drug aducanumab (rolls off the tongue). Biogen shares soared 38% on the news. It's a big deal — so big that the Nasdaq halted trading of Biogen shares ahead of the FDA's decision.
There's a catch... The FDA approved it on the condition that Biogen conduct another clinical trial. Many Alzheimer’s experts aren't happy with the approval and its mixed supporting data. Some aren't convinced the clinical trial data was enough to prove the drug works.
Drug stocks depend on drug pops... Which is why Biogen's five-year stock chart looks like a rollercoaster. In March 2015, Biogen stock was trading even higher than it was yesterday after it dropped positive early-stage data from an aducanumab trial (yep, the same Alzheimer's drug). Then in July 2015, Biogen released additional data about the trial that disappointed investors — and lost $20B in market value as its stock plunged. The results of Biogen’s next aducanumab trial could impact the stock again.
ID: 1